Eline Boon

Eline Boon

Auto-generated profile, based on publicly available information

Eline Boon

Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2018 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
EBEline Boon
Eline Boon
MBMiranda Bel
Miranda Bel
WBWim van Boxtel
Wim van Boxtel
WGWinette T. A. van der Graaf
Winette T. A. van der Graaf
RERobert J. J. van Es
Robert J. J. van Es
CHCarla van Herpen
Carla van Herpen
Salivary duct carcinoma (SDC) is a subtype of salivary gland cancer with a dismal prognosis and a need for better prognostication and novel treatments. The aim of this national cohort study was to investigate clinical outcome, prognostic factors, androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2) expression. SDC patients diagnosed between 1990 and 2014 were identified by the Nationwide Network and Registry of Histo‐ and Cytopathology in the Netherlands (PALGA). Subsequently, medical records were evaluated and pathological diagnoses reviewed. Data were analyzed for overall survival (OS), disease‐free survival (DFS), distant metastasis‐free survival (DMFS) and prognostic factors. AR was evaluated by immunohistochemistry (IHC), HER2 by IHC and fluorescent in‐situ hybridization. A total of 177 patients were included. The median age was 65 years, 75% were male. At diagnosis, 68% presented with lymph node metastases and 6% with distant metastases. Median OS, DFS and DMFS were 51, 23 and 26 months, respectively. In patients presenting without distant metastases, the absolute number of positive lymph nodes was associated with poor OS and DMFS in a multivariable analysis. AR and HER2 were positive in 161/168 (96%) and 44/153 (29%) tumors, respectively, and were not prognostic factors. SDC has a dismal prognosis with primary lymph node involvement in the majority of patients. The absolute number of lymph node metastases was found to be the only prognostic factor for DMFS and OS. AR expression and—to a lesser extent—HER2 expression hold promise for systemic treatment in the metastatic and eventually adjuvant setting.

22 December 2017 in Head & Neck
Verified
Journal Article
Open access
PDF file
EBEline Boon
Eline Boon
WBWim van Boxtel
Wim van Boxtel
JBJan Buter
Jan Buter
RJRobert J. Baatenburg de Jong
Robert J. Baatenburg de Jong
RERobert J. J. van Es
Robert J. J. van Es
CHCarla van Herpen
Carla van Herpen
Background: Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor‐positive. Only limited data are available on androgen deprivation therapy (ADT).Methods: Patients with advanced androgen receptor‐positive salivary duct carcinoma treated with first‐line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression‐free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care.Results: Thirty‐four of 35 patients who were ADT‐treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT‐treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P = .02).Conclusion: We recommend ADT in advanced androgen receptor‐positive salivary duct carcinoma given its response and clinical benefit. © 2017 Wiley Periodicals, Inc. Head Neck, 2017

10 August 2016 in Head & Neck
Verified
Journal Article
Open access
PDF file
EBEline Boon
Eline Boon
WGWinette T. A. van der Graaf
Winette T. A. van der Graaf
HGHans Gelderblom
Hans Gelderblom
MTMargot E. T. Tesselaar
Margot E. T. Tesselaar
RERobert J. J. van Es
Robert J. J. van Es
CHCarla van Herpen
Carla van Herpen
Background: There is an ongoing debate about the value of (neo‐)adjuvant chemotherapy in high‐ and intermediate‐grade osteosarcoma of the head and neck.Methods: All records of patients older than 16 years diagnosed with osteosarcoma of the head and neck in the Netherlands between 1993 and 2013 were reviewed.Results: We identified a total of 77 patients with an osteosarcoma of the head and neck; the 5‐year overall survival (OS) was 55%. In 50 patients with surgically resected high‐ or intermediate‐grade osteosarcoma of the head and neck younger than 75 years, univariate and multivariable analysis, adjusting for age and resection margins, showed that patients who had not received chemotherapy had a significantly higher risk of local recurrence (hazard ratio [HR] = 3.78 and 3.66, respectively).Conclusion: In patients younger than 75 years of age with surgically resected high‐ and intermediate‐grade osteosarcoma of the head and neck, treatment with (neo‐)adjuvant chemotherapy resulted in a significantly smaller risk of local recurrence. Therefore, we suggest (neo‐)adjuvant chemotherapy in patients amenable to chemotherapy. © 2016 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck 39: 140–146, 2017

1 September 2017 in Oral Oncology
Verified
Journal Article
Open access
WBWim van Boxtel
Wim van Boxtel
EBEline Boon
Eline Boon
WWWillem L.J. Weijs
Willem L.J. Weijs
FHFrank J.A. van den Hoogen
Frank J.A. van den Hoogen
UFUta E. Flucke
Uta E. Flucke
CHCarla van Herpen
Carla van Herpen

20 May 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EHErik Jacobus Van Helden
Erik Jacobus Van Helden
CMCatharina Wilhelmina Menke
Catharina Wilhelmina Menke
EBEline Boon
Eline Boon
SESuzanne van Es
Suzanne van Es
MHMarc C. Huisman
Marc C. Huisman
HVHenk Verheul
Henk Verheul
11519 Background: Despite RAS selection, one third of patients with metastatic RAS wild-type colorectal cancer (mCRC) do not benefit from anti-EGFR inhibitors. Therefore, an additional or more accurate predictive biomarker is needed to identify patients with primary resistant mCRC. Methods: In the IMPACT-CRC trial (NCT02117466) patients with chemotherapy refractory mCRC received 500 mg/m2 cetuximab every 2 weeks. Before the first dose and just before the second dose, patients underwent a 18F-FDG PET/CT (FDG PET). PET scans were quantitatively assessed by manual tumor delineation of ≤ 5 lesions, 2 per organ. Outcome is reported in total lesion glycolysis (TLG), defined as metabolic tumor volume times mean standard uptake value of the tumor. An optimal threshold to assess metabolic response was defined as decrease in TLG ≥15%. Quantitative data were correlated with CT evaluation after 8 weeks of treatment according to RECIST v1.1. Results: Out of 35 patients, 1 was excluded due to an infusion reaction. Median age was 64 years, 74% was male, 4 patients had a BRAF mutated tumor and 9 patients had right-sided primary tumors. 62% of patients had stable disease or partial response on CT after 8 weeks. At the time of this analysis, 88% of patients had progressive disease and 71% had died. Of the patients with right-sided tumors 11% had treatment benefit, compared to 80% in the left-sided group (p = 0.001). None of the 9 metabolic non-responders had treatment benefit, whereas 83% of the metabolic responders had treatment benefit according to RECIST v1.1. After adjustment for age, WHO score, BRAF mutation, sex and primary tumor site, FDG PET response remained correlated with PFS and OS (p = 0.002 and p = 0.014). Conclusions: Early evaluation of metabolic response after 1 dose of cetuximab is highly and independently predictive for treatment benefit with a 100% negative predictive value. Implementation of early FDG-PET evaluation in daily clinical practice can prevent unnecessary toxicity, costs of ineffective treatment and allows timely treatment adjustment for patients with mCRC undergoing anti-EGFR treatment. Clinical trial information: NCT02117466.

30 July 2025 in Clinical Breast Cancer
Verified
Journal Article
Open access
KHKarlijn E.P.E. Hermans
Karlijn E.P.E. Hermans
SGSandra M.E. Geurts
Sandra M.E. Geurts
FBFranchette Van Den Berkmortel
Franchette Van Den Berkmortel
JTJolien Tol
Jolien Tol
JHJoan B. Heijns
Joan B. Heijns
VTVivianne Tjan-Heijnen
Vivianne Tjan-Heijnen
The aim was to evaluate factors associated with taking 2 biopsies during the disease course of metastatic breast cancer (mBC) and to assess discordance rates for the oestrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2). Patients diagnosed with mBC in ten Dutch hospitals between 2007 and 2020 were retrieved from the SONABRE Registry (NCT-03577197). Patients were identified if they had at least 2 biopsies at different time points during their mBC disease course. Last follow-up was collected in September 2023. Frequencies and factors related to a second biopsy were studied using competing risk analysis with subdistribution hazard ratios (sHR). Discordance rates and factors associated with receptor subtype discordance were analysed using logistic regression using odds ratios (OR). Of 4,470 patients with mBC, 65% had 1 and 10% 2 biopsies during the course of mBC. Having 2 biopsies for mBC was related to age (sHR: 0.61), comorbidity (sHR: 0.76), WHO performance score (sHR: 0.30 for ≥2), initial TN subtype (sHR: 0.67), and initial metastatic site (sHR: 3.68 for soft tissue only), compared with the reference categories. Patients had an overall receptor subtype discordance of 23% compared to the second biopsy. Only HR+/HER2+ status was related to receptor subtype discordance (OR: 6.45). Only the minority of patients with mBC underwent a second biopsy during their mBC disease course. Receptor subtype heterogeneity is however frequent, particularly in patients with initially HR+/HER2+ mBC. Future studies are needed to guide treatment decisions as heterogeneity may play a role.